Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

and MIMEDX to provide advanced products for consistent wound management. In addition to the VALUE study, MediWound is preparing for a head-to-head Phase II study comparing EscharEx to collagenase ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Welcome to the AVITA Medical fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference ...